ClinicalTrials.gg
RecruitingNCT05052541Updated Jan 23, 2026

Safety and Efficacy of Oral Cannabis in Chronic Spine Pain

A Phase 3 interventional study of THC/CBD and THC in Back Pain and Neck Pain, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 21 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by University of Colorado, Denver · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
21 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Planned enrollment
81st of 262
157 · median 76
Started
2026
with 9 others
Phase 3
30 of 307
3 open now
Primary completion
2027-06
later than 30 of 50 live
Registered
233rd of 307
by date

Among the 307 studies in Back Pain with a site in United States, this one is the 81st largest by planned enrollment of the 262 interventional ones that give a count, is one of 10 that started in 2026, is one of 30 in phase 3, reaches primary completion later than 30 of the 50 other live ones, and was the 233rd registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 110 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

The overall objectives of this study are to investigate the efficacy of extended cannabis treatment to reduce patient exposure to prescription opioids through its use 1) as a non-opioid analgesic treatment, and 2) as a therapy for reducing high-dose opioid use in patients with chronic spine pain.

Read the detailed description

This randomized, placebo-controlled clinical trial is designed to elucidate the role of extended oral cannabis treatment in the alleviation of chronic spine pain and reduction of high-dose opioid use. This trial includes two study arms: Analgesia Arm and Reduction Arm. The Analgesia Arm uses a within-subject crossover design to determine whether daily treatment with an oral cannabis solution for 6 weeks significantly reduces spine pain compared to placebo. The Reduction Arm uses a parallel design to determine whether daily treatment with an oral cannabis solution for 13 weeks results in a greater reduction of pain and opioid intake than placebo treatment. It will also assess the impact of extended cannabis treatment on opioid craving and symptoms of opioid withdrawal in participants tapering their high-dose opioids.

03

Conditions studied

  • Back Pain
  • Neck Pain
04

Who can participate

Ages eligible
21 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.

Inclusion criteria

Inclusion Criteria:

Self-reported chronic (≥3 months' duration), non-radicular spine pain

Exclusion criteria

Exclusion Criteria:

Unwilling/unable to refrain from cannabis use (medical or recreational) for 14 days prior to Baseline Visit and throughout the study (other than study drug). This includes whole plant inhalation, edibles, extracts, and topicals.

Co-morbid cancer-related pain condition

Neuropathic Pain

A co-morbid pain condition that is of greater severity than the patient's spine pain

Spine or other major surgery within the 3 months prior to enrollment

Planned surgery or procedural intervention during the study period

Allergy or adverse reaction to cannabis

Current or historical substance use disorder

Current or historical alcohol use disorder

Current or prior cannabis abuse/dependence

Positive result for use of amphetamine/methamphetamine, barbiturates, benzodiazepines, cocaine, phencyclidine (PCP), ecstasy (MDMA), as detected on urine screen

Current use of valproate, clobazam, clopidogrel, warfarin, barbiturates, benzodiazepines

Prior adverse reaction to cannabis exposure (paranoia, anxiety, etc.)

History or diagnosis of schizophrenia, bipolar or a psychotic disorder

History of any mental health illness that in the opinion of the Investigator would compromise the safety of the participant

Current or historical severe depression

Current suicidal ideation

Diagnosed cognitive impairment (e.g. Alzheimer's Disease, traumatic brain injury)

Uncontrolled hypertension (>139/89)

Abnormal values on CBC (complete blood count) or CMP (comprehensive metabolic panel) laboratory analysis that are deemed by study physician

Known hepatic disease or dysfunction, or identification of such on screening laboratory studies

Known cardiovascular disease

Abnormal result on (ECG) that is deemed clinically significant by study MD

Cognitive disability that interferes with ability to provide consent or understand study procedure

History of seizure disorder

Any medical condition for which therapy is required.

Inability to refrain from using tobacco for at least 4 hours

Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data

Pending legal action or workers compensation

Pregnant females or females intending to become pregnant during the study period

Unwilling to use one of the accepted forms of during the study period and for at least 60 days after completion of the study (females of and males with sexual partners of childbearing potential)

Lactating females

Analgesia Arm Exclusion Criteria:

Unwilling/unable to discontinue current opioid use for 14 days prior to Baseline study visit and throughout the study

Reduction Arm Exclusion Criteria:

Not interested in reducing or discontinuing use of prescribed opioids for chronic pain

Unwilling to allow the study team to communicate with the participant's opioid prescribing provider

*Some inclusion/exclusion criteria are purposely omitted at this time to preserve scientific integrity. They will be included after the trial is complete.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
157 participants (estimated)

Study arms

  • Experimental
    Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then Placebo

    Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Analgesia Arm: THC, then Placebo, then THC/CBD

    Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Analgesia Arm: THC/CBD, then THC, then Placebo

    Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Analgesia Arm: THC/CBD, then Placebo, then THC

    Subjects in this crossover arm will be assigned to 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Analgesia Arm: Placebo, then THC, then THC/CBD

    Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Analgesia Arm: Placebo, then THC/CBD, then THC

    Subjects in this crossover arm will be assigned to 6 weeks on Placebo oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on THC oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD · Drug: THC · Drug: Placebo

  • Experimental
    Reduction Arm: THC/CBD

    Subjects in this parallel arm will be assigned to 13 weeks on THC/CBD oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: THC/CBD

  • Placebo comparator
    Reduction Arm: Placebo

    Subjects in this parallel arm will be assigned to 13 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in chronic pain as measured by the Visual Analog Scale (VAS) for pain

    The Visual Analog Scale (VAS) for pain is a 0-100mm visual scale anchored by "no pain" and "worst possible pain".

    Time frame: Weekly, up to week 22

  2. Change in opioid dose as measured in morphine milligram equivalents (MME)

    Time frame: Weekly, up to week 22

Secondary outcomes

  1. Study Drug Tolerability as measured by study drug use

    study drug dose, frequency

    Time frame: Daily, up to week 22

  2. Study Drug Tolerability as measured by side effects

    Time frame: Daily, up to week 22

  3. Change in spine-related disability and quality of life as measured on the NIH Patient Reported Outcomes Measurement System (PROMIS)-29

    The NIH Patient Reported Outcomes Measurement System (PROMIS)-29 is a collection of 4-item short forms assessing anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and ability to participate in social roles and activities as well as a single pain intensity item.

    Time frame: Weekly, up to week 22

  4. Change in spine-related disability and quality of life as measured on the NIH Task Force on Research Standards for Chronic Low-Back/Neck Pain Minimal Dataset

    The NIH Task Force on Research Standards for Chronic Low-Back Pain Minimal Dataset (and the modified Dataset for neck pain) assesses the influence of back/neck pain on physical function, emotional health, sleep, everyday activities.

    Time frame: Weekly, up to week 22

  5. Change in use of opioid and non-opioid analgesic medications

    Time frame: Daily, up to week 22

  6. Change in abuse liability of cannabis as measured on the Drug Effects Questionnaire (DEQ) for study drug (cannabis)

    The Drug Effects Questionnaire (DEQ) for study drug (cannabis) assesses the subjective effects after taking a drugs, including feeling a drug effect, liking/disliking the drug effect, feeling high, and wanting more drug.

    Time frame: Weekly, up to week 22

  7. Change in abuse liability of cannabis as measured on a VAS for study drug (cannabis) craving

    The VAS for study drug (cannabis) craving is a 100 mm visual scale anchored by "not at all" and "extremely" when asked about drug craving in the past week

    Time frame: Weekly, up to week 22

  8. Change in opioid craving and withdrawal as measured on a VAS for opioid craving

    The VAS for opioid craving is a 100 mm visual scale anchored by "not at all" and "extremely" when asked about opioid craving in the past week.

    Time frame: Weekly, up to week 22

  9. Change in opioid craving and withdrawal as measured on the Subjective Opiate Withdrawal Scale (SOWS)

    The Subjective Opiate Withdrawal Scale (SOWS) is a self-report questionnaire containing 16 symptoms related to opioid withdrawal.

    Time frame: Weekly, up to week 22

  10. Change in opioid craving and withdrawal as measured on the Drug Effect Questionnaire (DEQ)

    The Drug Effects Questionnaire (DEQ) for opioids assesses the subjective effects after taking opioids, including feeling a drug effect, liking/disliking the drug effect, feeling high, and wanting more opioids.

    Time frame: Weekly, up to week 22

  11. Change in opioid craving and withdrawal as measured on the Current Opioid Misuse Measure (COMM).

    Current Opioid Misuse Measure (COMM) is a brief patient self-assessment to help identify participants who exhibit aberrant behaviors associated with the misuse of opioid medications.

    Time frame: Weekly, up to week 22

  12. Change in pain sensitivity as measured by pain threshold (kPa) to a pressure stimulus

    Pressure output on a computer-controlled pressure algometer will be set to 10 kPa/s and participants will be instructed to indicate when the sensation changes from one of pressure alone to one of pressure and pain (pain threshold) by pressing a button on the remote-control indicator

    Time frame: Weekly, up to week 22

  13. Change in cognition as assessed by the List Sorting Working Memory Test

    The List Sorting Working Memory Test measures attention/working memory. Participants recall and sequence different visually and orally presented stimuli (e.g., participants are asked to list a set of given animals in order by size, from smallest to largest).

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  14. Change in cognition as assessed by the Pattern Comparison Processing Speed Test

    The Pattern Comparison Processing Speed Test is a measure of processing speed. Participants discern whether two side-by-side pictures are the same or not, with 85 seconds to respond to as many items as possible.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  15. Change in cognition as assessed by the Oral Symbol Digit Test

    The Oral Symbol Digit Test is a measure of processing speed. Symbols on the screen are associated with a number in a key. Participants are then presented symbols without numbers. Participants say each number that goes with each presented symbol for 90 seconds.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  16. Change in cognition as assessed by the Flanker Inhibitory Control and Attention Test

    The Flanker Inhibitory Control and Attention Test measures attention and inhibitory control. Participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli that surround it (i.e., the flankers, two on either side).

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  17. Change in cognition as assessed by the Picture Vocabulary Test

    The Picture Vocabulary Test measures receptive vocabulary. Respondents select pictures (from arrays) that most closely match the meanings of presented words.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  18. Change in cognition and motor skills as assessed by the Hopkins Verbal Learning Test Revised (HVLT-R)

    The HVLT-R is a measure of verbal learning and memory. Participants are asked to learn a 12-item word list over three trials (total immediate learning). A delayed free recall trial is administered after 20 minutes, followed by a yes/no recognition trial.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  19. Change in motor skills as assessed by the Grooved Pegboard Test

    The Grooved Pegboard is a test of fine motor coordination and speed. In this test, participants place 25 small metal pegs into holes on a 3"x3" metal board as quickly as possible. All pegs are alike and have a ridge on 1 side that corresponds to a randomly oriented notch in each hole on the metal board.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  20. Change in motor skills as assessed by the Standardized Field Sobriety Test

    The Standardized Field Sobriety Test is intended to detect driving impairments due to recent alcohol or drug use.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  21. Change in participant's perceived improvement in spine pain as measured on the Patient Global Impression of Change Scale (PGIC)

    The Patient Global Impression of Change Scale (PGIC) is a 7-point scale depicting a patient's rating of overall improvement.

    Time frame: Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

Other outcomes

  1. Change in 2-arachidonoylglycerol levels as measured in plasma

    2-arachidonoylglycerol will be measured in pmol/ml

    Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  2. Change in N-arachidonoylethanolamine levels as measured in plasma

    N-arachidonoylethanolamine will be measured in pmol/ml

    Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  3. Change in tumor necrosis factor alpha (TNF-α) levels as measured in plasma

    TNF-α will be measured in pg/ml

    Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

  4. Change in C-reactive protein (CRP) levels as measured in plasma

    CRP will be measured in mg/L

    Time frame: Baseline, Weeks 5, 13 and 21 (Analgesia Arm) Week 12 (Reduction Arm)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.

Of 16 phase 3 interventional studies under Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 62. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2021
First posted
Sep 22, 2021
StartEst.
Jan 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05052541
Collaborators
Institute of Cannabis Research
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Jan 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Mustafa Al-Mafrachi, MPH
Contact
spinepainstudy@cuanschutz.edu
303-724-0923
Emily Lindley, PhD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dronabinol · Cannabidiol

Start the discussion